Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy

Technology appraisal guidance
Reference number: TA242
Published: 25 January 2012

History

Background information

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): review decision - March 2015 information
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Appendix A - RPP decision paper March 2015 (PDF 72 KB)

Published:

25 March 2015
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): review proposal 9 February 2015 information
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendix A matrix of stakeholders (PDF 101 KB)

Published:

09 February 2015
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendix B - GE proposal paper January 2015 (PDF 621 KB)

Published:

09 February 2015

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): EIA form (scoping)

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): EIA form (scoping) (PDF 14 KB)

Published:

05 July 2012

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): EIA form (guidance development)

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): EIA form (guidance development) (PDF 20 KB)

Published:

05 July 2012

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final appraisal determination

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final appraisal determination information
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final appraisal determination document (PDF 377 KB)

Published:

25 November 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 57 KB)

Published:

25 November 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): consultee and commentator comments on the ACD
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Amgen (PDF 22 KB)

Published:

25 November 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Merck Serono (PDF 44 KB)

Published:

25 November 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Roche Products (PDF 80 KB)

Published:

25 November 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Nursing (PDF 18 KB)

Published:

25 November 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Pathologists (PDF 16 KB)

Published:

25 November 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Department of Health (PDF 9.7 KB)

Published:

25 November 2011

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appraisal consultation

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appraisal consultation
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appraisal consultation document information
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): evaluation report
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): overview (PDF 270 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): assessment report
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): assessment report (PDF 3.92 MB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): addendum to the assessment report (PDF 154 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendices (PDF 1.17 MB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): consultee and commentator comments on the assessment report
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Amgen (PDF 178 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Merck Serono (PDF 54 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Roche (PDF 51 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Nursing (PDF 110 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Pathologists (PDF 116 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Physicians (PDF 188 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Department of Health (PDF 69 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): response to consultee and commentator comments on the assessment report (PDF 313 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): manufacturer submissions (executive summary only)
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Amgen (PDF 84 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Merck Serono (PDF 108 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Roche (PDF 94 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): non-manufacturer submission
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Beating Bowel Cancer (PDF 417 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Bowel Cancer UK (PDF 342 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): expert written personal statements
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Beaumont (PDF 25 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Hochhauser (PDF 153 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Ilyas (PDF 37 KB)

Published:

05 September 2011
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Moss (PDF 219 KB)

Published:

05 September 2011

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): assessment report

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): assessment report (PDF 4.71 MB)

Published:

23 June 2011

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): protocol

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): protocol (PDF 100 KB)

Published:

23 November 2010

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final scope

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final scope (PDF 53 KB)

Published:

02 November 2010

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final matrix

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): final matrix (PDF 57 KB)

Published:

02 November 2010

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): comments on the draft scope

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): comments on the draft scope (PDF 126 KB)

Published:

02 November 2010

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Comments on the provisional matrix

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Comments on the provisional matrix (PDF 41 KB)

Published:

02 November 2010

Colorectal cancer (metastatic) following the failure of first line chemotherapies - bevacizumab, cetuximab and panitumumab (review): draft scope

Colorectal cancer (metastatic) following the failure of first line chemotherapies - bevacizumab, cetuximab and panitumumab (review): draft scope (PDF 33 KB)

Published:

04 August 2010

Colorectal cancer (metastatic) following the failure of first line chemotherapies - bevacizumab, cetuximab and panitumumab (review): provisional matrix

Colorectal cancer (metastatic) following the failure of first line chemotherapies - bevacizumab, cetuximab and panitumumab (review): provisional matrix (PDF 35 KB)

Published:

04 August 2010